Pharmacokinetics and pharmacodynamics of cloprednol.
The pharmacokinetics and pharmacodynamics of cloprednol after oral administration in doses of 2.5 to 15 mg to healthy volunteers were determined. The half-life of cloprednol ranged from 1.8 h to 2.7 h, the oral clearance (CL/F) was determined to be 15-22 l/h. Since cloprednol shows nonlinear plasma protein binding, the plasma concentrations were converted to their free, unbound concentrations for the PK/PD-analysis. Due to this nonlinearity, the half-life of free, unbound cloprednol was shorter than that of the total drug. For the assessment of pharmacodynamics, differential white blood cell counts were obtained over 24 hours. An integrated pharmacokinetic-pharmacodynamic (PK/PD) approach using a modified Emax-model was applied to link unbound corticosteroid concentrations to the effect on lymphocytes and granulocytes. The E50 value for unbound cloprednol ranged from 3.6 to 4.7 ng/ml and 1.2 to 4.6 ng/ml for granulocytes and lymphocytes, respectively. The PK/PD model allowed a good prediction of the observed effects and was consistent with reported values for glucocorticoid receptor binding affinities for cloprednol.
Möllmann
H
H
Medical Clinic Bergmannsheil, University of Bochum, Germany.
Hochhaus
G
G
Rohatagi
S
S
Barth
J
J
Derendorf
H
H
Krieg
M
M
Weisser
H
H
Möllmann
A C
AC
D000284:Administration, Oral; D000328:Adult; D004305:Dose-Response Relationship, Drug; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D011282:Pregnenediones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology
D011282:Pregnenediones; C011731:cloprednol